A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
Public ClinicalTrials.gov record NCT00920764. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects Who Are Currently Being Treated With an Renin-Angiotensin System Inhibitor
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study objective is to investigate the effects of three low doses of atrasentan on urinary albumin/creatinine ratio (UACR) levels in subjects with Type 2 diabetic nephropathy. Patients with Type 2 diabetes with nephropathy must be receiving a renin-angiotensin system inhibitor, such as an Angiotensin converting enzyme inhibitor (ACEi) or an Angiotensin II Receptor Blocker (ARB) for participation in this study. ACEi and ARB treatment are the standard of care for the management of proteinuria in Chronic Kidney Disease (CKD) patients.
Study identification
- NCT ID
- NCT00920764
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 92 participants
Conditions and interventions
Conditions
Interventions
- Placebo for Atrasentan 0.2 mg/mL solution Drug
- 0.25 mg Atrasentan QD Drug
- 0.75 mg Atrasentan QD Drug
- 1.75 mg Atrasentan QD Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2009
- Primary completion
- Mar 31, 2010
- Completion
- Apr 30, 2010
- Last update posted
- Jun 5, 2018
2009 – 2010
United States locations
- U.S. sites
- 24
- U.S. states
- 11
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 19386 | Tempe | Arizona | 85284 | — |
| Site Reference ID/Investigator# 25043 | Azusa | California | 91702 | — |
| Site Reference ID/Investigator# 23308 | Los Angeles | California | 90022 | — |
| Site Reference ID/Investigator# 25430 | Los Angeles | California | 90048 | — |
| Site Reference ID/Investigator# 20421 | San Diego | California | 92123 | — |
| Site Reference ID/Investigator# 22442 | San Diego | California | 92123 | — |
| Site Reference ID/Investigator# 21061 | Whittier | California | 90603 | — |
| Site Reference ID/Investigator# 16572 | Yuba City | California | 95991 | — |
| Site Reference ID/Investigator# 26142 | Coral Gables | Florida | 33134 | — |
| Site Reference ID/Investigator# 16567 | Hudson | Florida | 34667 | — |
| Site Reference ID/Investigator# 16577 | Pembroke Pines | Florida | 33028 | — |
| Site Reference ID/Investigator# 25242 | Pembroke Pines | Florida | 33028 | — |
| Site Reference ID/Investigator# 16569 | Rockville | Maryland | 20852 | — |
| Site Reference ID/Investigator# 16574 | Omaha | Nebraska | 68131 | — |
| Site Reference ID/Investigator# 20221 | Buffalo | New York | 14215 | — |
| Site Reference ID/Investigator# 16576 | Greenville | North Carolina | 27834 | — |
| Site Reference ID/Investigator# 16573 | Morehead City | North Carolina | 28557 | — |
| Site Reference ID/Investigator# 26143 | Statesville | North Carolina | 28625 | — |
| Site Reference ID/Investigator# 19383 | Bethlehem | Pennsylvania | 18017 | — |
| Site Reference ID/Investigator# 26365 | Orangeburg | South Carolina | 29115 | — |
| Site Reference ID/Investigator# 16571 | San Antonio | Texas | 78229-4801 | — |
| Site Reference ID/Investigator# 16566 | San Antonio | Texas | 78229 | — |
| Site Reference ID/Investigator# 19384 | San Antonio | Texas | 78229 | — |
| Site Reference ID/Investigator# 24542 | Fairfax | Virginia | 22030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00920764, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2018 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00920764 live on ClinicalTrials.gov.